Hansoh Pharmaceutical Group Officially Launches Global Operations Headquarters and R&D Center

On November 29, Hansoh Pharmaceutical Group Company Limited held the inauguration ceremony for its global operations headquarters and R&D center, officially announcing their launch. This marks the company’s full entry into a new chapter of pharmaceutical innovation and international strategy.

Hansoh Pharma's Global Operations Headquarters Building is located in the core area of Zhangjiang Science City, adjacent to the Yangtze River Delta National Innovation Center. In 2011, Shanghai Hansoh Biomedical Technology Co., Ltd. was established in Zhangjiang, becoming one of the first local innovative pharmaceutical companies to take root in Zhangjiang. In early 2021, Hansoh Pharma’s biopharmaceutical R&D center in the Zhangjiang Park was put into operation. In mid-October, the official signing for Hansoh Pharma’s Global R&D Headquarters project also took place in Zhangjiang, marking a significant event in the company’s continued efforts to deepen its innovation-driven drug R&D and industrialization strategy. In November, Hansoh Pharma officially launched its Global Operations Headquarters and R&D Center. Hansoh Pharma stated that the company will fully leverage its strategic location advantages, remain at the forefront of global innovation, and embark on a new journey of pharmaceutical innovation and internationalization.

Hansoh Pharma's main operating entity, Jiangsu Hengsen Pharmaceutical Group Co., Ltd., was founded in 1995 in Lianyungang, Jiangsu. It has now developed into one of China’s leading innovation-driven listed pharmaceutical companies. The company focuses on major therapeutic areas such as oncology, central nervous system, anti-infectives, and diabetes. It has established research and development centers in Maryland, USA, as well as in Shanghai and Lianyungang, China, continuously enhancing its international innovative capabilities. The company has consistently ranked among the top 30 in the Top 100 List of China's Pharmaceutical Industry and among the top 3 Best Industrial Enterprises in China's Pharmaceutical R&D Product Lines for many years. It was listed on the Hong Kong Stock Exchange in June 2019 (HK.03692).

Hansoh Pharma stated that in the future, the company will continue to rely on the multiple resource advantages of the Zhangjiang pharmaceutical industry, and through continuous scientific and technological innovation, accelerate transformation and upgrading. The company is committed to effectively promoting the benefits of domestically developed innovative achievements to patients in China and even globally, improving human health and quality of life.